Zaire ebolavirus envelope glycoprotein GP1,2 (GP1,2)

Zaire ebolavirus envelope glycoprotein GP1,2 is a viral envelope glycoprotein complex essential for Ebola virus infectivity. It is synthesized as a single precursor and then post-translationally cleaved by host furin into two subunits, GP1 and GP2, which remain linked by disulfide bonds[6][2]. GP1 mediates attachment to host cells via receptor binding, while GP2 is responsible for the fusion of viral and cellular membranes[5][2]. The GP1,2 trimer forms the characteristic surface spikes of the virus and is highly glycosylated, including extensive N- and O-linked sugar modifications, which contribute to immune evasion by masking neutralizing epitopes[7][2][1]. GP is the primary target for host neutralizing antibodies, therapeutic monoclonal antibodies, and is used as a vaccine antigen in licensed Ebola vaccines. Mutations or structural changes in this protein can influence virus transmissibility, virulence, and resistance to antibodies[1][3][7]. The abundance of soluble glycoprotein (sGP) in plasma is also leveraged as a clinical biomarker for Ebola virus disease[2]. GP1,2 is considered an archetypal class I fusion protein and shares structural similarities with HIV-1 and influenza virus envelope glycoproteins[5].

Other names

Ebola virus glycoproteinEbola GPEbolavirus GP1,2Envelope glycoprotein GP

Prevention of virus-host attachment (neutralizing antibodies block GP1 receptor-binding site); Inhibition of membrane fusion (antibodies or small molecules disrupt GP2-mediated fusion); Immune targeting (vaccines elicit anti-GP immune response)